The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | The future of targeted therapies for advanced colorectal cancer
Kristen Ciombor, MD, Vanderbilt Health, Nashville, TN, provides an overview of advances in targeted therapies for advanced colorectal cancer. Current actionable targets include BRAF, HER2, RAS, and microsatellite instability (MSI) high, as well as rarer mutations such as NTRK. Recent studies have suggested moving targeted therapies to earlier lines of treatment, and the KEYNOTE-177 (NCT02563002) and CheckMate 142 (NCT02060188) trials have demonstrated the utility of immunotherapy in the first-line setting for MSI-high colorectal cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: https://bit.ly/3DcSevZ
